Look back at pharma news to Aug 10

13 August 2017

How the USA views the UK’s state reimbursement came up for comment last week, following the recent approval by the National Institute for Health and Care Excellence (NICE) of Eli Lilly’s cancer drug Lartruvo. Also attracting attention were MyoKardia’s heart drug mavacamten, Valeant Pharmaceutical International not getting US approval for its eye drug candidate latanoprostene bunod, and Dermira’s acquisition of Roche cast-off lebrikizumab, a dermatology candidate.

Lilly’s new sarcoma drug gets the thumbs up from UK payers

Writing on the Seeking Alpha blog, Zach Hartman noted that the interesting litmus tests he has noticed since starting to take a deeper dive into pharma news is the reimbursement schemes from large, social healthcare systems. Specifically, whether institutes like the NICE in the UK give the thumbs up can be a really strong indicator that a drug's cost/benefit is seen as up to snuff.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK